In the last trading session, 1.2 million Protalix BioTherapeutics Inc (AMEX:PLX) shares changed hands as the company’s beta touched 0.49. With the company’s per share price at $2.35 changed hands at -$0.1 or -4.08% during last session, the market valuation stood at $173.04M. PLX’s last price was a discount, traded about -17.45% off its 52-week high of $2.76. The share price had its 52-week low at $0.82, which suggests the last value was 65.11% up since then. When we look at Protalix BioTherapeutics Inc’s average trading volume, we note the 10-day average is 0.94 million shares, with the 3-month average coming to 657.45K.
Protalix BioTherapeutics Inc (AMEX:PLX) trade information
Instantly PLX was in red as seen at the end of in last trading. With action 3.98%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 25.00%, with the 5-day performance at 3.98% in the green. However, in the 30-day time frame, Protalix BioTherapeutics Inc (AMEX:PLX) is -12.64% down. Looking at the short shares, we see there were 5.05 million shares sold at short interest cover period of 8.4 days.
Protalix BioTherapeutics Inc (PLX) estimates and forecasts
Year-over-year growth is forecast to reach 50.73% up from the last financial year.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 21.6M. 1 analysts are of the opinion that Protalix BioTherapeutics Inc’s revenue for the current quarter will be 23.1M. The company’s revenue for the corresponding quarters a year ago was 3.68M and 13.3M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 487.44%. The estimates for the next quarter sales put growth at 73.63%.
The 2025 estimates are for Protalix BioTherapeutics Inc earnings to increase by 675.00%.
PLX Dividends
Protalix BioTherapeutics Inc is expected to release its next quarterly earnings report on 2025-Mar-16.
Protalix BioTherapeutics Inc (AMEX:PLX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 13.70% of Protalix BioTherapeutics Inc shares while 5.98% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 6.93%. There are 5.98% institutions holding the Protalix BioTherapeutics Inc stock share, with MILLENNIUM MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 1.1106% of the shares, roughly 0.81 million PLX shares worth $0.95 million.
RENAISSANCE TECHNOLOGIES LLC holds the second largest percentage of outstanding shares, with 1.1016% or 0.8 million shares worth $0.94 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were Unified Series Trust-Auer Growth Fd and Bridgeway Funds Inc-Ultra Small Company Market Fund . With 200.0 shares estimated at $0.47 million under it, the former controlled 0.27% of total outstanding shares. On the other hand, Bridgeway Funds Inc-Ultra Small Company Market Fund held about 0.24% of the shares, roughly 180.0 shares worth around $0.42 million.
